Comparison of Three Commercially Available Serologic Assays Used To Detect Human Parvovirus B19-Specific Immunoglobulin M (IgM) and IgG Antibodies in Sera of Pregnant Women
- 1 July 2004
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 42 (7) , 3191-3195
Abstract
A split-sample study was conducted to evaluate the performances of three enzyme immunoassays (EIAs) utilizing one or more conformational antigens to detect human parvovirus B19 (B19V)-specific immunoglobulin M (IgM) or IgG in the sera of 198 pregnant women. We compared EIAs available from Biotrin International, Inc. (Dublin, Ireland), Medac Diagnostika (Wedel, Germany), and Mikrogen (Martinsried, Germany). Specimens with discordant results were analyzed further using an immunofluorescence assay (Biotrin). Equivocal data accounted for close to half of all the discrepant results for both IgM and IgG, with 7 of 15 discrepant results from the Medac and Mikrogen kits involving equivocal data and the Biotrin kit giving a single equivocal result. For each specimen, a consensus was established from the four test results if agreement occurred among at least three of four results. Overall, the highest percentage of agreement with the consensus results was seen when Biotrin kits were used; 194 (100%) of 194 and 194 (99.5%) of 195 results for IgM and IgG, respectively, agreed with the consensus results. When Medac kits were used, 189 (97.4%) of 194 and 191 (97.9%) of 195 results for IgM and IgG, respectively, agreed with the consensus, and when Mikrogen kits were used, 179 (92.3%) of 194 and 193 (99%) of 195 results for IgM and IgG, respectively, agreed with the consensus. Given the consensus results, the Medac EIA appeared to generate presumed false-positive results for IgM and the Mikrogen EIA appeared to generate presumed false-positive results for IgG and IgM. In summary, the Biotrin EIAs produced far fewer equivocal results than the other assays and results of the Biotrin EIAs agreed more often with the consensus results than did those of the other commercially available EIAs for detecting B19V-specific IgM and IgG antibodies.Keywords
This publication has 20 references indexed in Scilit:
- Appreciating the differences between immunoassays used to diagnose maternal parvovirus B19 infection: understanding the antigen before interpreting the resultsPrimary Care Update for OB/GYNS, 2002
- Parvovirusinfection in womenPrimary Care Update for OB/GYNS, 2002
- Evaluation of four commercial enzyme immunoassays for detection of immunoglobulin M antibodies to human parvovirus B19European Journal of Clinical Microbiology & Infectious Diseases, 1996
- IgG subclass response to human parvovirus B19 infectionClinical and Diagnostic Virology, 1996
- Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalisAmerican Journal of Obstetrics and Gynecology, 1996
- Epitope Type-Specific IgG Responses to Capsid Proteins VP1 and VP2 of Human Parvovirus B19The Journal of Infectious Diseases, 1995
- The Incidence of Human Parvovirus B19 Infection during Pregnancy and Its Impact on Perinatal OutcomeThe Journal of Infectious Diseases, 1995
- Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease.BMJ, 1990
- Human Parvovirus Infection in Pregnancy and Hydrops FetalisNew England Journal of Medicine, 1987
- Experimental Parvoviral Infection in HumansThe Journal of Infectious Diseases, 1985